A Phase 2, Open-Label Trial Of Dacomitinib (PF-00299804) In Selected Patients With Advanced Adenocarcinoma Of The Lung
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Dacomitinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 19 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
- 03 Nov 2014 Planned number of patients changed from 114 to 119, as per ClinicalTrials.gov record.